

NEW BRUNSWICK DRUG PLANS NIRMATRELVIR/RITONAVIR (PAXLOVID) SPECIAL AUTHORIZATION REQUEST

Request forms must be completed and retained with the prescription at the pharmacy.

Please do not fax completed form to the New Brunswick Drug Plans.

Pharmacies must submit claims electronically and include the CPhA intervention code that corresponds to the clinical criteria below.

Section 1 – Requestor Information	Section 2 – Patient Information
First Name	First Name
Last Name	Last Name
Mailing Address (Street, City, Province, Postal Code)	Medicare Number 123456789
Telephone Fax	Date of Birth (DD/MM/YYYY)

Section 3 – Drug Requested

Drug Name	Dose and Regimen (maximum 5 days)
☑ nirmatrelvir/ritonavir (Paxlovid)	

Section 4 – Therapeutic Information

□ Tested positive for COVID-19 and symptoms began in the last 5 days; OR □ A prescription was written for future use. The patient will fill the prescription only if they have tested positive for COVID-19 and are within 5 days of symptom onset;

AND is 18 years of age or older, and meets one of the following clinical criteria (select one):

Clinical Criteria	Intervention Code
 Severely immunosuppressed due to one or more of the following: Solid organ transplant Receiving treatment for a malignant hematologic condition Bone marrow transplant, stem cell transplant or transplant-related immunosuppressant use Received an anti-CD20 therapy or B-cell depleting therapy (such as rituximab) in the previous two years Severe primary immunodeficiencies Other (please specify):	UT
 Moderately immunosuppressed due to one or more of the following: Receiving treatment for cancer including solid tumors Receiving treatment with significantly immunosuppressing drugs (e.g., biologic in the past three months, oral immune-suppressing drug in the past month, oral glucocorticoid [20 mg per day of prednisone equivalent taken on an ongoing basis] in the past month, or immune-suppressing infusion or injection in the past three months). Advanced HIV infection 	VE
 Moderate primary immunodeficiencies Renal conditions (i.e., hemodialysis, peritoneal dialysis, glomerulonephritis treated with a glucocorticoid, estimated glomerular filtration rate [eGFR] less than 15 mL/min/1.73 m²) Other (please specify):	

Section 5 – Requestor's Signature

ORM-1238E 05/24 Signature License or Registration Number Date (DD/MM/YYYY) This information is collected under the authority of the Prescription and Catastrophic Drug Insurance Act, or the Prescription Drug Payment Act. This

information will be used and disclosed to administer the NB Drug Plans (New Brunswick Prescription Drug Program and New Brunswick Drug Plan). It may be used and disclosed in accordance with the Personal Health Information Privacy and Access Act.